Loading...
Levomilnacipran for the treatment of major depressive disorder: a review
Levomilnacipran (LVM, Fetzima(®)) was recently approved by the US Food and Drug Administration for the treatment of major depressive disorder. It is a unique dual neurotransmitter reuptake inhibitor. In contrast with other selective serotonin norepinephrine reuptake inhibitors, including duloxetine,...
Na minha lista:
| Udgivet i: | Neuropsychiatr Dis Treat |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4295915/ https://ncbi.nlm.nih.gov/pubmed/25657584 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S54710 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|